drugset / Trial / NCT01853423
Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream
Phase 1
Completed
11 enrolled
Le Bonheur Children's Hospital
Pfizer · collabUniversity of Tennessee · collab
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the safety and efficacy of a 0.1% formulation of rapamune cream in children with Tuberous Sclerosis Complex (TSC), ages 3 years and older, who have facial angiofibromas that would benefit from treatment.
Timeline
- Start
- 2013-10
- Primary completion
- 2016-05
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 0.1 % | Topical |